IM

Immix Biopharma IncNASDAQ IMMX Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0.045

Micro

Exchange

XNAS - Nasdaq

IMMX Stock Analysis

IM

Uncovered

Immix Biopharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.045

Dividend yield

Shares outstanding

13.927 B

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The company went IPO on 2021-12-16. The firm is developing a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Its lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology. IMX-110, which is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology is used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor/apoptosis inducer.

View Section: Eyestock Rating